These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB. Gerke C; Colucci AM; Giannelli C; Sanzone S; Vitali CG; Sollai L; Rossi O; Martin LB; Auerbach J; Di Cioccio V; Saul A PLoS One; 2015; 10(8):e0134478. PubMed ID: 26248044 [TBL] [Abstract][Full Text] [Related]
7. Development of FAcE (Formulated Alhydrogel competitive ELISA) method for direct quantification of OAg present in Shigella sonnei GMMA-based vaccine and its optimization using Design of Experiments approach. Necchi F; Carducci M; Pisoni I; Rossi O; Saul A; Rondini S J Immunol Methods; 2019 Aug; 471():11-17. PubMed ID: 31039338 [TBL] [Abstract][Full Text] [Related]
8. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study. Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434 [TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and immunogenicity of the Frenck RW; Conti V; Ferruzzi P; Ndiaye AGW; Parker S; McNeal MM; Dickey M; Granada JP; Cilio GL; De Ryck I; Necchi F; Suvarnapunya AE; Rossi O; Acquaviva A; Chandrasekaran L; Clarkson KA; Auerbach J; Marchetti E; Kaminski RW; Micoli F; Rappuoli R; Saul A; Martin LB; Podda A EClinicalMedicine; 2021 Sep; 39():101076. PubMed ID: 34430837 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R; Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766 [TBL] [Abstract][Full Text] [Related]
15. Dissecting the contribution of O-Antigen and proteins to the immunogenicity of Shigella sonnei generalized modules for membrane antigens (GMMA). Mancini F; Gasperini G; Rossi O; Aruta MG; Raso MM; Alfini R; Biagini M; Necchi F; Micoli F Sci Rep; 2021 Jan; 11(1):906. PubMed ID: 33441861 [TBL] [Abstract][Full Text] [Related]
16. A phase I trial of WRSS1, a Raqib R; Sarker P; Zaman K; Alam NH; Wierzba TF; Maier N; Talukder K; Baqui AH; Suvarnapunya AE; Qadri F; Walker RI; Fix A; Venkatesan MM Hum Vaccin Immunother; 2019; 15(6):1326-1337. PubMed ID: 30794051 [No Abstract] [Full Text] [Related]
17. Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults. Pitisuttithum P; Islam D; Chamnanchanunt S; Ruamsap N; Khantapura P; Kaewkungwal J; Kittitrakul C; Luvira V; Dhitavat J; Venkatesan MM; Mason CJ; Bodhidatta L Clin Vaccine Immunol; 2016 Jul; 23(7):564-75. PubMed ID: 27146000 [TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Oaks EV; Turbyfill KR Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513 [TBL] [Abstract][Full Text] [Related]
19. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Orr N; Katz DE; Atsmon J; Radu P; Yavzori M; Halperin T; Sela T; Kayouf R; Klein Z; Ambar R; Cohen D; Wolf MK; Venkatesan MM; Hale TL Infect Immun; 2005 Dec; 73(12):8027-32. PubMed ID: 16299296 [TBL] [Abstract][Full Text] [Related]